• news-review-featured-image
  • Tecfidera® and Tysabri® data show improved outcomes in early MS treatment
  • Posted in News Review

  • 28th Apr 2017

  •   Real-World Data Further Support Efficacy of Dimethyl Fumarate in Newly Diagnosed and Early Switch Patients MS Patients with High Disease Activity Benefit from Early and Continued Natalizumab Treatment. Biogen have announced new real-world data that show treatment with its leading multiple sclerosis (MS) therapies, TECFIDERA® (dimethyl fumarate) and TYSABRI® (natalizumab), early in the course of the disease may […]

  • news-review-featured-image
  • Study confirms Apomorphine subcutaneous infusion’s established role in PD
  • Posted in News Review

  • 27th Apr 2017

  • Results from the first randomised, controlled trial investigating the efficacy and safety of APO-go®/MOVAPO® (apomorphine) subcutaneous infusion in Parkinson’s disease (PD) patients whose motor symptoms are not controlled by other therapies – the TOLEDO study – were presented during the ‘Emerging Science’ session at the American Academy of Neurology (AAN) Annual Meeting in Boston, USA, […]

  • michele-hu-for-en
  • Why get involved in research?
  • Posted in News Review

  • 10th Jun 2016

  • Podcast: Michele Hu discusses with Parkinson’s UK how her work as a neurologist and a researcher drives forward the search for better treatments and a cure

  • Download news-review-featured-image
  • Evaluation by MS Trust reveals vital MS services face critical challenges
  • Posted in News Review

  • 13th Nov 2015

  • Vital NHS services that people living with MS rely on are facing increasing pressures which could lead to inequities in care, according to a major new report published by the MS Trust. Evidence for MS specialist services, the findings from the MS Trust’s three-year GEMSS evaluation project, provides an unprecedented insight into the state of […]

Page 1 of 41234
SIGN UP FOR OUR MAILING LIST

Open Access, for medical professionals: Sign up to receive our email newsletter with links to the latest content. ACNR is free, thanks to the support of advertisers. The editorial content is peer reviewed and remains completely independent unless clearly specified. 

We may infrequently send you news from our sponsors which is relevant to the field of neurology, but you can opt out at any time.

This website is for medical professionals only.